Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.
Adult
Cohort Studies
Demyelinating Diseases
/ cerebrospinal fluid
Female
Humans
Immunoglobulin A
/ biosynthesis
Immunoglobulin G
/ biosynthesis
Immunoglobulin M
/ biosynthesis
Male
Multiple Sclerosis, Relapsing-Remitting
/ cerebrospinal fluid
Oligoclonal Bands
/ cerebrospinal fluid
Prospective Studies
Severity of Illness Index
Journal
JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
pubmed:
30
4
2019
medline:
19
6
2020
entrez:
30
4
2019
Statut:
ppublish
Résumé
Reliable biomarkers associated with disability worsening in multiple sclerosis (MS) are still needed. To determine a possible association of intrathecal IgG synthesis and early disability worsening as measured by Expanded Disability Status Scale (EDSS) scoring in patients with relapsing-remitting MS or clinically isolated syndrome. Cerebrospinal fluid measurements and clinical data from the observational longitudinal German national multiple sclerosis cohort were analyzed. Patients were recruited between August 2010 and November 2015 from 18 centers. Data analysis was completed from August 2018 to December 2018. Patients were offered standard immunotherapies per national treatment guidelines. A possible association between intrathecal IgG synthesis and risk of EDSS worsening 4 years after study inclusion was tested as the primary end point by multivariable binomial regression analysis. Kaplan-Meier analysis with a log-rank test was used to assess the association of intrathecal IgG synthesis with the time to EDSS worsening. Associations between intrathecal IgM or IgA synthesis and other cerebrospinal fluid parameters and EDSS worsening were analyzed as exploratory end points. Data collection began before the hypotheses were formulated. Of all 1376 patients in the German Competence Network of Multiple Sclerosis cohort, 703 patients were excluded owing to missing cerebrospinal fluid or EDSS data. Of the 673 included patients, 459 (68.2%) were women. The mean (SD) age at baseline was 34 (10) years. Intrathecal IgG synthesis was associated with a higher risk of EDSS worsening after 4 years (odds ratio, 2.02 [95% CI, 1.15-3.58]; P = .01), independent of the occurrence of relapses and disease-modifying therapy. Additionally, intrathecal IgG synthesis was associated with earlier EDSS worsening; 4 years after study entry, worsening occurred in 28.4% (95% CI, 22.7%-34.1%) and 18.1% (95% CI, 12.4%-23.9%) of patients with and without intrathecal IgG synthesis, respectively. No association of other routine cerebrospinal fluid parameters with EDSS worsening was found. Patients with new diagnoses of relapsing-remitting multiple sclerosis or clinically isolated syndrome with intrathecal IgG synthesis had a higher risk of and shorter time to EDSS worsening across a 4-year period of follow-up. Intrathecal IgG synthesis is a potentially useful marker for disability worsening in patients with multiple sclerosis and may be useful for early treatment decisions.
Identifiants
pubmed: 31034002
pii: 2731584
doi: 10.1001/jamaneurol.2019.0905
pmc: PMC6583696
doi:
Substances chimiques
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Oligoclonal Bands
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-849Références
Neurol Neuroimmunol Neuroinflamm. 2016 Sep 07;3(5):e279
pubmed: 27648465
Neuron. 2006 Oct 5;52(1):61-76
pubmed: 17015227
Acta Neurol Scand. 2002 Mar;105(3):158-63
pubmed: 11886357
Mult Scler. 2008 Nov;14(9):1208-13
pubmed: 18755821
J Neurol Neurosurg Psychiatry. 2009 Mar;80(3):292-6
pubmed: 18829628
Eur J Neurol. 2007 Jul;14(7):797-800
pubmed: 17594338
Neurology. 2002 Aug 27;59(4):555-9
pubmed: 12196648
Arch Neurol. 2010 Nov;67(11):1329-35
pubmed: 20625068
J Neuroimmunol. 2013 Apr 15;257(1-2):76-81
pubmed: 23434160
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 01;5(3):e446
pubmed: 29511705
Neuroradiology. 2012 Jan;54(1):5-12
pubmed: 21327771
Brain. 2008 Mar;131(Pt 3):808-17
pubmed: 18234696
Brain. 1991 Apr;114 ( Pt 2):1045-56
pubmed: 2043940
Neurology. 2006 Jan 24;66(2):172-7
pubmed: 16434648
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Mult Scler. 2015 Jul;21(8):1013-24
pubmed: 25680984
Dis Markers. 2013;35(6):687-99
pubmed: 24324285
Degener Neurol Neuromuscul Dis. 2017 Jan 12;7:19-29
pubmed: 30050375
BMC Neurol. 2015 May 13;15:79
pubmed: 25966681
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Brain. 2010 Jul;133(Pt 7):1914-29
pubmed: 20534650
J Clin Invest. 2005 Jan;115(1):187-94
pubmed: 15630459
Brain. 2015 Jul;138(Pt 7):1863-74
pubmed: 25902415
Arch Neurol. 2005 Jun;62(6):865-70
pubmed: 15956157
J Neurol Neurosurg Psychiatry. 1980 Feb;43(2):102-5
pubmed: 7359146
J Neurol Sci. 2009 Apr 15;279(1-2):21-5
pubmed: 19181345
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14
pubmed: 23431079
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
Brain. 2003 Apr;126(Pt 4):770-82
pubmed: 12615637
Brain. 1997 Nov;120 ( Pt 11):2059-69
pubmed: 9397021
J Neurol. 2016 Dec;263(12):2499-2504
pubmed: 27730374
Neurology. 1985 Jun;35(6):813-7
pubmed: 3889705
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902
pubmed: 8057110
Mult Scler. 2004 Aug;10(4):469-71
pubmed: 15327048